Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor
Nov 20, 2008 08:02 AM
- SuperGen Appoints David Bearss, Ph.D., Chief Scientific Officer
Nov 17, 2008 08:03 AM
- SuperGen to Present at the Lazard Capital Markets Fifth Annual Healthcare Conference on November 18, 2008
Nov 13, 2008 02:24 PM
- SuperGen to Present at the Fifth Annual Lazard Healthcare Conference on November 18, 2008
Nov 13, 2008 08:02 AM
- /UPDATED RELEASE -- SuperGen, Inc./
Nov 07, 2008 09:01 PM
- SuperGen Reports 2008 Third Quarter Financial Results
Nov 04, 2008 04:01 PM
- SuperGen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 10, 2008
Nov 03, 2008 01:09 PM
- SuperGen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 10, 2008
Nov 03, 2008 08:04 AM
- SuperGen to Announce 2008 Third Quarter Financial Results November 4, 2008
Oct 28, 2008 08:03 AM
- SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
Oct 23, 2008 06:01 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
SUPG
|
Compare to S&P
|
| YTD |
-49.86 %
|
-0.01 %
|
| 4 Weeks |
45.24 %
|
71.94 %
|
| 12 Weeks |
13.66 %
|
76.55 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 87.50 %
|
|
EPS Growth in Last Year: 50.00 %
|
|
Sales Growth in Last Quarter: 25.53 %
|
|
Sales Growth in Last Quarter: 66.73 %
|
|
|
